Detalles de la búsqueda
1.
Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022.
Emerg Infect Dis
; 28(10): 2119-2121, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35997692
2.
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
J Intern Med
; 291(1): 72-80, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34459525
3.
IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden.
Cytokine
; 159: 156020, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36057230
4.
Impact of monocyte-related modulators and kidney function on mortality in hospitalized patients with COVID-19.
Scand J Immunol
; 96(5): e13215, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36950896
5.
Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report.
Arterioscler Thromb Vasc Biol
; 41(2): 878-882, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33267656
6.
Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.
Arterioscler Thromb Vasc Biol
; 41(2): 988-994, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33267662
7.
"Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19".
BMC Nephrol
; 23(1): 299, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056305
8.
Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.
N Engl J Med
; 389(17): 1626-1628, 2023 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37888924
9.
Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.
J Med Virol
; 93(10): 5908-5916, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34138483
10.
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.
N Engl J Med
; 387(14): 1333-1336, 2022 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36103621
11.
Response by Mackman et al to Letter Regarding Article, "Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report".
Arterioscler Thromb Vasc Biol
; 41(6): e381-e382, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34038165
12.
Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality.
Am J Hematol
; 96(4): E98-E100, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33393103
13.
Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers.
JAMA
; 325(19): 2015-2016, 2021 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33825846
14.
Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.
Front Immunol
; 15: 1346749, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558811
15.
Tissue factor activity of small and large extracellular vesicles in different diseases.
Res Pract Thromb Haemost
; 7(3): 100124, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37012986
16.
Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers.
Nat Commun
; 14(1): 1577, 2023 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36949041
17.
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.
Clin Transl Immunology
; 11(4): e1388, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35444806
18.
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Vaccines (Basel)
; 10(3)2022 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35334989
19.
A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies.
N Biotechnol
; 66: 46-52, 2022 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34628049
20.
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.
PLoS One
; 17(1): e0262169, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35020778